食管癌加速超分割放疗后长期生存患者生活质量调查

Study on long-term quality of life of patients treated with accelerated hyperfractionated radiotherapy for esophageal carcinoma

目的 评估加速超分割放射治疗食管癌患者的长期生活质量。方法 应用食管癌放射治疗后晚期放射治疗反应主客观处理分析 (SOMA)量表、症状自评量表 (SCL 90 )和生活满意度指数A表 (LSI A) ,综合分析食管癌加速超分割放射治疗后长期生存患者的生活质量 ,包括躯体功能状况、精神心理状态及自我生活满意度情况 ,并与健康对照组做对比研究。结果 与健康对照组相比 ,加速超分割治疗组SCL 90评分和LSI A指数差异无显著性 ;治疗组中 ,连续加速超分割 (CAHF)和后程加速超分割 (LCAF)两组之间晚期放射反应、SCL 90评分和LSI A差异亦无显著性。结论 (1)初步研究结果显示 ,加速超分割放射治疗食管癌长期生存患者能保持较好的生活质量 ,包括躯体功能状况、精神心理状态及较高的自我生活满意度评价 ;(2 )CAHF与LCAF两种放射分割治疗方案对食管癌患者长期生活质量的影响差异无显著性 ;(3)食管癌患者长期生活质量的评价方法尚需进一步摸索 ,并需扩大病例数及建立对照样本。

Objective To evaluate long-term quality of life of patients treated with accelerated hyperfractionated radiotherapy for esophageal carcinoma.Methods SOMA scale,Symptom Checklist 90(SCL 90) and Life Satisfaction Index A (LSIA) questionnaire were mailed to the long term survivors treated with accelerated hyperfractionated radiotherapy for esophageal carcinoma for assessment of long term quality of life including physical symptoms,psychological status and life satisfactory evaluation. Control group was also used.Results There was no significant difference between accelerated hyperfractionated radiotherapy group and control group in terms of the scoring of quality of life such as SCL 90 and LSI A. While in the treatment group,there was also no significant difference between continuous accelerated hyperfractionated(CAHF) and late course accelerated hyperfractionated (LCAF)subgroups according to the scoring of quality of life such as late radiation reaction,SCL-90 and LSI-A.Conclusions (1)Preliminary results demonstrated that long-term survivors treated with accelerated hyperfractionated radiotherapy for esophageal carcinoma retain good quality of life including physical symptoms,psychological status and life satisfactory evaluation.(2)Preliminary results demonstrated that there is no significant difference in long term quality of life between the two groups.(3)Methods of evaluation for long term quality of life for patients treated with esophageal carcinoma needs further investigation.Involvement of more patients and establishment of control group are also worthwhile.